New prostate cancer drug enters first human trials

NCT ID NCT07570979

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 15, 2026 · Updated 3 times

Summary

This early-stage trial tests a new oral drug called INR731, alone or with standard hormone therapy drugs, in 208 men with metastatic prostate cancer that no longer responds to hormone treatment. The main goals are to check safety, find the right dose, and see if the drug shows any signs of shrinking tumors. Participants must have advanced cancer that has spread and meet specific health criteria.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: INR731 (oral drug)
What this could lead to: If successful, this could point toward a new treatment option for metastatic prostate cancer that is resistant to hormone therapy.
What could go wrong: This is an early Phase 1 trial with only 208 participants, so the drug may not prove effective or may have significant side effects. It is too early to know if it will work.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)

Contacts and locations

Locations

Mary Crowley Cancer Research
RECRUITING

Dallas, Texas, 75251, United States
Novartis Investigative Site
RECRUITING

Melbourne, Victoria, 3000, Australia
Novartis Investigative Site
RECRUITING

Hirakata, Osaka, 5731191, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.